Course Summary

Thiothixene is an antipsychotic medication that belongs to the class of thioxanthenes. It is primarily used to treat schizophrenia and other psychotic disorders, effectively alleviating symptoms such as hallucinations, delusions, and disorganized thinking. Thiothixene blocks certain neurotransmitter receptors, particularly dopamine receptors, in the brain, thereby reducing the excess dopamine activity associated with psychotic conditions. Though effective, thiothixene may cause side effects such as drowsiness, dizziness, and movement disorders. The use of thiothixene has significantly declined in recent decades with the advent of the newer atypical antipsychotics, however, it continues to be manufactured and used in many countries worldwide.

Course Format

Homestudy

Course Syllabus

  1. Introduction
  2. Pharmacological Profile and Uses
    • Dosing and Available Forms
    • Dosing Adjustment: Geriatric Patients
    • Dosing Adjustment: Hepatic and Renal Impairment
  3. Thiothixene Contraindications, Adverse Effects, and Warnings
    • Potential Adverse Effects
    • Pregnancy and Breastfeeding
    • Drug-Drug Interactions and Withdrawal/Discontinuation
  4. Thiothixene Overdose
  5. Case Study: Thiothixene Wrongful Administration
  6. Summary

Author

Richard Daniels, PharmD, BCPS

Richard “Cole” Daniels earned his Doctor of Pharmacy(PharmD) from the Skaggs School of Pharmacy at the University of Montana in 2018. Throughout pharmacy school he completed a 3-year internship at Community Medical Center in Missoula, Montana in which he gained valuable experience in an acute care setting. Cole currently serves as a psychiatric clinical staff pharmacist at the Montana State Hospital. He has over 11 years of pharmacy experience having worked in several settings including retail, acute care, and inpatient psychiatric care. Cole has a diverse set of interests. However, acute care medicine, infectious disease, pain management, and asthma/COPD are a primary focus of his at the Montana State Hospital. He obtained board certification as a certified pharmacotherapy specialist in the Spring of 2022.